A phase-2 study of pembrolizumab in patients with biologically selected subtypes of relapsed/refractory aggressive lymphomas.
作者信息
Merrill Mwanasha H, Redd Robert A, Fisher David C, Abramson Jeremy S, Barnes Jeffrey, Choi Jaehyuk, Jacobson Caron A, Kim Austin I, Lunning Matthew A, Jester Hallie D, Jeter Erin L, McDonough Mikaela M, Armand Philippe, Jacobsen Eric D
机构信息
Department of Hematology-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Massachusetts General Hospital, Boston, MA, USA.
出版信息
Leuk Lymphoma. 2025 Jul;66(7):1354-1357. doi: 10.1080/10428194.2025.2478525. Epub 2025 Mar 25.
Abstract
摘要
Zotero 插件